Crystec, trading as CrystecPharma, have developed a unique system which crystallises drugs into novel particles, enhancing the delivery and performance of medicines. Their expert team works with the global pharmaceutical and healthcare industry to solve drug particle formation, formulation and process challenges. With funds raised, they will match grant-funding to continue a project with Chinese partners to improve drugs for respiratory disease, as part of the InnovateUK Newton Fund Research and Innovation Bridges Programme.
Performance in every particle
We work with clients in the global pharmaceutical and healthcare industry to improve the formulation and efficacy of drugs, to ultimately raise the quality of life for patients. We also develop our own innovative therapies in important areas of unmet clinical need, including women’s health, urology and respiratory disease.
CrystecPharma has extensive experience in pharmaceutical development. Our team have pioneered the application of SCF to pharmaceuticals and consists of acknowledged leaders in relevant fields of science, drug delivery, engineering, scale-up, manufacturing and medicine, underpinned by senior-level pharmaceutical industry and licensing experience.
With funds raised, we will match grant-funding to continue a project with Chinese manufacturers, as part of the InnovateUK Newton Fund Research and Innovation Bridges Programme*, to improve drugs for asthma and COPD. Current medications either aerosolise poorly or are too expensive for widespread use in China, where there is a high rate of respiratory disease, exacerbated by air pollution. With our SCF technology, we can alter the medicine to aerosolise more easily, in more simple and affordable devices. Ultimately it is hoped that this project will lead to improved access to better respiratory medicines for patients in China and the rest of the world.
*The Newton Fund aims to promote the economic development and social welfare of either partner country.
Where will the funds go?
A. Hi Darryl, thanks again for your question. Our interest receivable increased slightly over the period 2017-18, whilst our interest payable decreased over the same period. Again, there is no real pattern here. Interest received due to modest cash balances in accounts in UK and China. Interest paid on previous loan which is now fully paid off. As above, we try to use working capital as fully as we can to support our core strategy of investing in developing better medicines.
A. Hi Darryl, thank you for your quesiton. Crystec is an R&D focused company, seeking to maximise value of its IP prior to license/IPO. As such we seek to minimise profits and maximise investment in research. The tax rebates relate to R&D tax credits, which vary from year to year depending on actual expenditure (including capital) vs eligible allowance after government grants. There is no real pattern here, other than we have received two large grant awards (AMSCI and InnovateUK) in recent years.
Back to the top
"Performance in every particle"
powered by Equifax